Integra LifeSciences Holdings Corp Stock
The price for the Integra LifeSciences Holdings Corp stock decreased slightly today. Compared to yesterday there is a change of -€0.100 (-0.920%).
Currently there is a rather negative sentiment for Integra LifeSciences Holdings Corp with 1 Buy predictions and 4 Sell predictions..
With a target price of 10 € there is a slightly negative potential of -7.41% for Integra LifeSciences Holdings Corp compared to the current price of 10.8 €.
Pros and Cons of Integra LifeSciences Holdings Corp in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Integra LifeSciences Holdings Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Integra LifeSciences Holdings Corp | -0.920% | -7.692% | -4.425% | -51.786% | 1.887% | -79.623% | -80.541% |
| Icu Medical Inc. | 0.000% | 1.527% | 6.400% | -17.391% | 7.258% | -18.405% | -25.281% |
| Bio-Rad Labs Inc. A | -1.060% | 0.072% | 5.995% | -17.110% | 7.639% | -33.920% | -44.257% |
| Neogen Corp. | 3.700% | -1.205% | 36.667% | -27.434% | 33.333% | - | - |
Comments
Integra LifeSciences (NASDAQ:IART) had its price target lowered by analysts at Citigroup Inc. from $12.00 to $11.00. They now have a "sell" rating on the stock.
Show more
Ratings data for IART provided by MarketBeat
Integra LifeSciences (NASDAQ:IART) had its price target raised by analysts at JPMorgan Chase & Co. from $12.00 to $13.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for IART provided by MarketBeat
Integra LifeSciences (NASDAQ:IART) had its "sell" rating reaffirmed by analysts at Citigroup Inc..
Show more
Ratings data for IART provided by MarketBeat
News
Integra (IART) Q2 Revenue Beats by 5%
Integra LifeSciences (NASDAQ:IART), a medical technology company specializing in neurosurgery, reconstructive, and tissue technologies, released its results for Q2 2025 on July 31, 2025. The most
